Stockreport

Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's Disease [Yahoo! Finance]

Soligenix, Inc.  (SNGX) 
NASDAQ:AMEX Investor Relations: soligenix.com/investors
PDF Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announce [Read more]